KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ginkgo Bioworks Holdings (DNA) Long-Term Investments (2021 - 2023)

Ginkgo Bioworks Holdings filings provide 3 years of Long-Term Investments readings, the most recent being $78.6 million for Q4 2023.

  • On a quarterly basis, Long-Term Investments rose 4991.7% to $78.6 million in Q4 2023 year-over-year; TTM through Dec 2023 was $78.6 million, a 4991.7% increase, with the full-year FY2023 number at $78.6 million, up 4991.7% from a year prior.
  • Long-Term Investments hit $78.6 million in Q4 2023 for Ginkgo Bioworks Holdings, up from $1.1 million in the prior quarter.
  • In the past five years, Long-Term Investments ranged from a high of $121.8 million in Q1 2023 to a low of $37629.0 in Q2 2021.
  • Median Long-Term Investments over the past 3 years was $47.5 million (2021), compared with a mean of $54.1 million.
  • The widest YoY moves for Long-Term Investments: up 236600.42% in 2022, down 98.49% in 2022.
  • Ginkgo Bioworks Holdings' Long-Term Investments stood at $102.0 million in 2021, then tumbled by 98.49% to $1.5 million in 2022, then soared by 4991.7% to $78.6 million in 2023.
  • The last three reported values for Long-Term Investments were $78.6 million (Q4 2023), $1.1 million (Q3 2023), and $119.9 million (Q2 2023) per Business Quant data.